BenQ Medical Technology (4116) Fundamentals 2026 — P/E 25.3x, Revenue Analysis | SniperIQ
BenQ Medical Technology (4116) is a TW-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of NT
8.70 on the TWO. This SniperIQ fundamentals page covers BenQ Medical Technology's valuation (P/E 25.3x, P/B 6.6x), profitability (net margin 1.3%), revenue (NT$5.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is BenQ Medical Technology's market cap?
BenQ Medical Technology (4116) has a market capitalization of approximately NT
8.70 on the TWO. Market cap moves with the live share price.What is BenQ Medical Technology's P/E ratio?
BenQ Medical Technology's trailing twelve-month P/E ratio is 25.3x, with a price-to-book (P/B) of 6.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is BenQ Medical Technology?
BenQ Medical Technology runs a net profit margin of 1.3%, a gross margin of 31.4%, and an operating margin of 6.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does BenQ Medical Technology generate?
BenQ Medical Technology reported revenue of NT$5.3B for fiscal year 2025, with net income of NT$78M and earnings per share (EPS) of 1.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does BenQ Medical Technology pay a dividend?
BenQ Medical Technology offers a trailing dividend yield of about 5.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is BenQ Medical Technology financially healthy?
BenQ Medical Technology carries a debt-to-equity ratio of 2.06x and a current ratio of 1.59x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is BenQ Medical Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BenQ Medical Technology (4116) the key facts are: market cap NT
Track BenQ Medical Technology's full fundamentals live
Get BenQ Medical Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.